Edgewise Therapeutics (EWTX) Capital Expenditures (2020 - 2026)
Edgewise Therapeutics (EWTX) reported Capital Expenditures of $41000.0 for Q1 2026, down 6.82% on a YoY basis from $44000.0 in Q1 2025, and down 73.03% sequentially from $152000.0 in Q4 2025.
Edgewise Therapeutics (EWTX) Capital Expenditures (2020 - 2026) Analysis & Trends
Edgewise Therapeutics (EWTX) has 7 years of Capital Expenditures data on file, last reported at $41000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 6.82% year-over-year to $41000.0; the trailing twelve-month figure through Mar 2026 stood at $196000.0 (up 450.0% YoY), and the FY2025 full-year result was $199000.0, up 352.27% from the prior year.
- Capital Expenditures fell to $41000.0 in Q1 2026, from $152000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $4.4 million in Q1 2023 to a low of -$994000.0 in Q4 2024.
- A 5-year average of $502294.1 and a median of $161000.0 in 2023 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures soared 1313.59% in 2023 and sank 717.39% in 2024, its largest moves.
- Tracing EWTX's Capital Expenditures over 5 years: stood at $257000.0 in 2022, then tumbled by 37.35% to $161000.0 in 2023, then slumped by 717.39% to -$994000.0 in 2024, then jumped by 115.29% to $152000.0 in 2025, then sank by 73.03% to $41000.0 in 2026.
- Business Quant data shows EWTX's Capital Expenditures at $41000.0 in Q1 2026, $152000.0 in Q4 2025, and -$31000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Edgewise Therapeutics | 4.21 Bn | 4.21 Bn | - | 41,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41,000.00 |
| Mar 31, 2026 | 41,000.00 |
| Dec 31, 2025 | 152,000.00 |
| Dec 31, 2025 | 152,000.00 |
| Sep 30, 2025 | -31,000.00 |
| Sep 30, 2025 | -31,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | -994,000.00 |
| Dec 31, 2024 | -994,000.00 |
| Sep 30, 2024 | 922,000.00 |
| Sep 30, 2024 | 922,000.00 |
| Jun 30, 2024 | -28,000.00 |
| Jun 30, 2024 | -28,000.00 |
| Mar 31, 2024 | 144,000.00 |
| Mar 31, 2024 | 144,000.00 |
| Dec 31, 2023 | 161,000.00 |
| Dec 31, 2023 | 161,000.00 |